Service de Réanimation Médical et Toxicologique
Paris, 75010, France
Location status: Recruiting
NCT Number: NCT02514655
Hypothesis: Nosten® device is able to reduce the time of underinflated balloon and removes excess pressure. This device may thus reduce the risk of ventilator-acquired pneumonia (VAP) and early tracheal lesions resulting from intubation with decreased discomfort, morbidity, and nursing workload.
The main objective of the investigators is to show that Nosten® device is more effective than monitoring and manual inflation of the balloon of the tracheal tube to prevent VAP occurrence.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Paris, 75010, France
Location status: Recruiting
Multicenter, controlled, prospective randomized open study with blinded assessment of the primary endpoint. Two groups are set up: one experimental group with the control of the cuff pressure by the Nosten® device versus one control group with the manual monitoring of the cuff pressure and inflation of the balloon.
Inclusion: All orotracheally intubated patients for an expected period > 48 hours will be selected. Inclusion will be decided using an algorithm adapted to each center to limit the number of inclusion per month without any biases.
The total number of required insclusion is 500, or 250 / group. This calculation is based on the assumption that a frequency of 25% of patients having at least one VAP in the reference strategy, ensuring a 80% power in the detection by Chi-2 test with a difference 10%. A bilateral risk of first species determined at 5% was considered.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One experimental group with the control of the cuff pressure by Nosten® device
One control group with the manual monitoring of the cuff pressure and inflation of the balloon
Time frame: up to 3 months
To prove that the Nosten® device is more effective than monitoring and manual inflation of the catheter balloon in reducing the occurrence of VAP.
Time frame: up to 3 months
using the bacteriological examination of the tracheal aspiration during the intensive care hospitalization
Time frame: up to 3 months
before obtaining microbiological results needed to affirm the Ventilator-Acquired Pneumonia (VAP) according to the criteria of the American Thoracic Society (3 months)
Time frame: up to 3 months
Reduction of clinically suspected Ventilator-Acquired Pneumonia (VAP)
Time frame: up to 3 months
Using Nosten® device
Time frame: up to 3 months
using the tracheal ischemia score [Touat L. Intensive Care Med 2014]
Contact information is provided by the study sponsor or research team.
Assistance Publique - Hôpitaux de Paris
Other
Role of a Simple Mechanical Device of Pressure Control in the Balloon of the Endotracheal Tube to Prevent Ventilator-acquired Pneumonia
Acronym: PAV-PROTECT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06466980
Cardiac Arrest With Successful Resuscitation, Cardiovascular Diseases
Corbeil-Essonnes, France
View Trial DetailsNCT07463339
Critical Illness, Cross Infection
View Trial DetailsNCT06848010
Cross Infection, Disease Attributes
Milan, Italy
View Trial DetailsNCT07129733
Critical Illness, Cross Infection
Passos, Minas Gerais, Brazil
View Trial Details